Sagility Ltd – Moderate View (Hold Rating): Balanced Prospects with Some Caution

Sagility Ltd, a Bengaluru-based provider of technology-enabled business process solutions to U.S. healthcare payers and providers, has shown respectable growth and operational improvement in recent quarters, but given the valuation, client concentration and strategic risks, a “Hold” stance seems prudent for now rather than outright buy or sell. For instance, in Q1 FY26 the company posted revenue of ₹1,538.9 crore (≈ US$180.4 million), up 25.8% YoY (23.1% in constant currency) and reported adjusted EBITDA of ₹368.7 crore (24.0% margin) and adjusted PAT of ₹199.7 crore (13.0% margin), reflecting decent leverage expansion and margin progression. For FY25 the firm delivered ~17.2% growth (revenue ~₹5,569.9 crore), adjusted EBITDA margin of ~26.4%, and adjusted PAT margin ~14.6%, signalling improving profitability and strong operating cash-flow conversion (OCF/EBITDA ~89.7%). On the positives, Sagility’s deep focus on U.S. healthcare payer/provider services — a niche but expanding market — means it benefits from structural tailwinds in outsourced revenue-cycle management, analytics and digital transformation. It has a strong client base, long-standing contracts (five largest client groups with average tenure ~18 years) and global delivery scale across multiple countries. Moreover, the company has shown margin expansion, operational improvement and decent growth visibility. However, several caveats support a more cautious rating. The valuation appears elevated relative to near-term earnings: as per sources, ROCE/ROE remain modest (ROE ~7–9% as noted via Screener) and the business is still navigating risk of client concentration (U.S. payer segment dominance) and macro / regulatory uncertainty in healthcare outsourcing. Also, the promoter stake dilution via the large OFS (~₹2,671 crore stake sale by promoter entity) triggered a significant negative sentiment earlier in the year.